• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Biomarker Test

    ID: MRFR/LS/2428-CR
    200 Pages
    Rahul Gotadki
    April 2025

    Numerous companies specialize in the development and commercialization of biomarker tests, which are used for diagnosing, monitoring, and predicting the progression of various diseases. These tests play a critical role in improving patient outcomes and advancing personalized medicine.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Biomarker Tests Market Research Report - Global Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Biomarker Test Market


    Biomarker Tests Key Companies*Disclaimer: List of key companies in no particular orderLatest biomarker tests Companies Update


    • July 2023: Quest Diagnostics introduced a biomarker test for prostate cancer with the goal of enhancing the precision of biopsy grading. The diagnosis and evaluation of patients with prostate cancer rely heavily on the correct interpretation and grading of tissue. It's possible, though, that appearance doesn't match reality when it comes to biology. However, this year, researchers in Australia claimed to have developed a panel that might "transform clinical practice" by identifying biomarkers that describe prostate cancer biology.




    • September 2023: Oxford BioDynamics, Plc, a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, today announced validation of its EpiSwitch Prostate Screening (PSE) blood test in its US clinical laboratory, allowing men at risk for prostate cancer to immediately have access to its highly accurate PSE test. The PSA score and five epigenetic biomarkers are used together in the PSE test to determine whether or not prostate cancer is present. Patients whose PSE results indicate a low risk of cancer are not automatically referred for a destructive and invasive biopsy, but rather placed on active monitoring and retested at a later date. In all likelihood, a visit to a urologist would be required for therapy.




    • July 2023: LucentAD, a test to aid in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease (AD), was released by Quanterix Corporation, a company that fuels scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection. When used in conjunction with other diagnostic techniques, the LucentAD test will let doctors to rapidly and easily determine whether or not a patient has amyloid pathology typical of Alzheimer's disease.


    List of biomarker tests Key companies in the market

    • Hoffmann-La Roche AG

    • Novartis AG

    • Pfizer Inc.

    • GlaxoSmithKline plc

    • GE Healthcare

    • Medtronic plc

    • Quest Diagnostics